Discovery of WNT9B Gene Mutation Significantly Increases Prostate Cancer Risk
/in Observational/by MaxEcDNA and Prostate Cancer: A New Frontier in Understanding Resistance
/in Preclinical Research/by MaxHydrogel Breakthrough May Improve Cancer Vaccines
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxNewsletter 4/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi, fellow fighters! I’m back on track. This past week was packed with new clinical trial information. I want to highlight the ever-increasing role of AI in drug discovery—we are truly living in a transformative time. As usual, we also have a […]
Phase 1 Trial: Pocenbrodib, A New (AI Based) Approach for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Study: Evofosfamide With Immune Checkpoint Inhibitors for Advanced Cancers
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 1 Trial: JANX007 Plus JANX013 Combo in mCRPC / mAPMR September 14, 2026
- CRISPR Takes Another Step Forward September 14, 2026
- A STEAP1 ADC That May Turn Tumour Killing Into an Immune Response September 14, 2026
- Soon to be Phase 1 for ICP-B381, a New Bispecific Antibody-Drug Conjugate for mCPRC September 14, 2026